LON:CRTX CRISM Therapeutics (CRTX) Share Price, News & Analysis GBX 8 -0.25 (-3.03%) As of 04:14 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsNews and Trends About CRISM Therapeutics Stock (LON:CRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CRISM Therapeutics alerts:Sign Up Key Stats Today's Range 8▼ 8.2550-Day Range 8▼ 11.4052-Week Range 8▼ 18.50Volume143,260 shsAverage Volume258,561 shsMarket Capitalization£6.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview CRISM Therapeutics Corporation is clinical stage company, having developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective. CRISM will initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma in Q1 2026. For more information please visit: https://www.crismtherapeutics.com Read More Receive CRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CRISM Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRTX Stock News HeadlinesCRISM Therapeutics Sets AGM Date as Phase 2 Glioblastoma Trial Recruitment BeginsOctober 2, 2026 | tipranks.comCRISM Therapeutics Reveals Concentrated Shareholder Base After Register AnalysisJuly 27, 2026 | tipranks.comMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found. | Crypto 101 Media (Ad)CRISM Therapeutics Upsizes Oversubscribed Retail Offer to Fund Cancer Drug Delivery TrialsMay 28, 2026 | tipranks.comCRISM Therapeutics Raises Funds for Glioblastoma TrialDecember 15, 2025 | tipranks.comCRISM Therapeutics Launches £100,000 Retail Offer to Fund Clinical TrialDecember 10, 2025 | tipranks.comCRISM Therapeutics Secures £1 Million for Phase 2 Glioblastoma TrialDecember 10, 2025 | tipranks.comCRISM Therapeutics Secures Approval for Phase 2 Glioblastoma TrialSeptember 1, 2025 | tipranks.comSee More Headlines CRTX Stock Analysis - Frequently Asked Questions How have CRTX shares performed this year? CRISM Therapeutics' stock was trading at GBX 9 on January 1st, 2026. Since then, CRTX shares have decreased by 11.1% and is now trading at GBX 8. How were CRISM Therapeutics' earnings last quarter? CRISM Therapeutics Corporation (LON:CRTX) posted its quarterly earnings data on Monday, September, 21st. The company reported GBX (2.60) earnings per share for the quarter. How do I buy shares of CRISM Therapeutics? Shares of CRTX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Company Calendar Last Earnings9/21/2026Today11/13/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMaterials Industry Metals & Mining Sub-IndustryN/A Current SymbolLON:CRTX CIKN/A Webwww.crismtherapeutics.com Phone(212) 918-4934FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (4.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£792.20 thousand Net MarginsN/A Pretax MarginN/A Return on Equity-119.45% Return on Assets-26.77% Debt Debt-to-Equity RatioN/A Current Ratio8.10 Quick RatioN/A Sales & Book Value Annual Sales£352 thousand Price / Sales18.10 Cash FlowN/A Price / Cash FlowN/A Book ValueGBX 43.03 per share Price / Book0.19Miscellaneous Outstanding Shares79,657,000Free FloatN/AMarket Cap£6.37 million OptionableN/A Beta0.59 Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (LON:CRTX) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISM Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISM Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
